United States (US) Companion Diagnostics Market (2025-2031) | Forecast, Trends, Growth, Share, Outlook, Competitive Landscape, Companies, Segmentation, Size & Revenue, Analysis, Value, Industry

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United States (US) Country Macro Economic Indicators

3.2 United States (US) Companion Diagnostics Market Revenues & Volume, 2021 & 2031F

3.3 United States (US) Companion Diagnostics Market - Industry Life Cycle

3.4 United States (US) Companion Diagnostics Market - Porter's Five Forces

3.5 United States (US) Companion Diagnostics Market Revenues & Volume Share, By Technology Type, 2021 & 2031F

3.6 United States (US) Companion Diagnostics Market Revenues & Volume Share, By Indication, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of cancer and other chronic diseases in the US, driving the demand for companion diagnostics.

4.2.2 Advancements in personalized medicine and targeted therapies, leading to the adoption of companion diagnostics.

4.2.3 Rising focus on precision medicine and value-based healthcare, creating opportunities for companion diagnostics market growth.

4.3 Market Restraints

4.3.1 Stringent regulatory requirements for approval and commercialization of companion diagnostics, leading to longer timelines and higher costs.

4.3.2 Limited reimbursement policies and coverage for companion diagnostics, hindering market penetration.

4.3.3 Challenges in integrating companion diagnostics into existing healthcare systems and workflows, affecting adoption rates.

6.1 United States (US) Companion Diagnostics Market, By Technology Type

6.1.1 Overview and Analysis

6.1.2 United States (US) Companion Diagnostics Market Revenues & Volume, By Technology Type, 2021- 2031F

6.1.3 United States (US) Companion Diagnostics Market Revenues & Volume, By Immunohistochemistry, 2021- 2031F

6.1.4 United States (US) Companion Diagnostics Market Revenues & Volume, By Polymerase Chain Reaction (PCR), 2021- 2031F

6.1.5 United States (US) Companion Diagnostics Market Revenues & Volume, By Next Generation Sequencing (NGS), 2021- 2031F

6.1.6 United States (US) Companion Diagnostics Market Revenues & Volume, By In Situ Hybridization, 2021- 2031F

6.1.7 United States (US) Companion Diagnostics Market Revenues & Volume, By Others, 2021- 2031F

6.2 United States (US) Companion Diagnostics Market, By Indication

6.2.1 Overview and Analysis

6.2.2 United States (US) Companion Diagnostics Market Revenues & Volume, By Oncology, 2021- 2031F

6.2.3 United States (US) Companion Diagnostics Market Revenues & Volume, By Neurology, 2021- 2031F

6.2.4 United States (US) Companion Diagnostics Market Revenues & Volume, By Others, 2021- 2031F

7.1 United States (US) Companion Diagnostics Market Export to Major Countries

7.2 United States (US) Companion Diagnostics Market Imports from Major Countries

8.1 Adoption rate of companion diagnostics by healthcare providers and institutions.

8.2 Number of companion diagnostic tests approved by regulatory authorities for use in the US market.

8.3 Investment and funding trends in companion diagnostics companies and research initiatives.

8.4 Patient outcomes and treatment efficacy improvements attributed to the use of companion diagnostics.

8.5 Collaboration and partnerships between pharmaceutical companies, diagnostic companies, and research institutions in the field of companion diagnostics.

9.1 United States (US) Companion Diagnostics Market Opportunity Assessment, By Technology Type, 2021 & 2031F

9.2 United States (US) Companion Diagnostics Market Opportunity Assessment, By Indication, 2021 & 2031F

10.1 United States (US) Companion Diagnostics Market Revenue Share, By Companies, 2024

10.2 United States (US) Companion Diagnostics Market Competitive Benchmarking, By Operating and Technical Parameters